Abstract: This invention provides estrogen receptor modulators of formula 1, having the structure 1

Abstract: This invention provides compounds of Formula I having the structure wherein, A, X, Y, Z, W, R1, R2, R3, R4, R5, and R6 are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

Abstract: This invention provides compounds of Formula I having the structure 1

Abstract: This invention provides compounds of Formula I having the structure wherein: A, B, R1, R2, R3, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

Abstract: This invention provides compounds of Formula I having the structure wherein, A, X, Y, Z, W, R1, R2, R3, R4, R5, and R6 are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

Abstract: This invention provides compounds of Formula I having the structure 1

Abstract: This invention provides compounds of Formula I having the structure wherein: R is hydrogen or alkyl of 1-6 carbon atoms; A is R1, R2, R3 are each, independently, hydrogen, alkoxy of 1-6 carbon atoms, thioalkyl of 1-6 carbon atoms, trifluoromethyl, R4 is hydrogen, alkyl of 1-6 carbon atoms, halogen, or alkoxy of 1-6 carbon atoms; R5 is phenyl, naphthyl, thienyl, furyl, wherein R5 may be optionally mono-, di-, or tri-substituted with a sustituent selected from the group consisting of alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, halogen, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms, and dialkylamino in which each of the alkyl groups is of 1-6 carbon atoms, nitro, cyano, —CO2H, alkylcarbonyloxy of 2-7 carbon atoms, and alkylcarbonyl of 2-7 carbon atoms; m=1-4; n=1-4; and X=O, S, or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders relat

Abstract: This invention provides compounds of Formula I having the structure ##STR1## wherein: A, B, R1, R2, R3, R4, R5, and R6 are as defined in the specification,or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

Abstract: This invention relates to compounds which inhibit lipoxygenase in the metabolism of arachidonic acid and thus inhibits formation of leukotrienes which are implicated in inflammatory processes and bronchoconstriction and inhibits the oxidation of LDL which is implicated in formation of atherosclerotic plaque.The compounds useful in this invention are represented by the formula: ##STR1## wherein: R.sup.2 is hydrogen, halogen or C.sub.1 -C.sub.6 alkyl; Y of O or S;R.sup.5 is hydrogen or methylR.sup.6 is --NH.sub.2, --CH.sub.3 or --OCH.sub.3 ;and R.sup.1 is ##STR2## wherein R.sup.7, R.sup.8 and R.sup.10 are independently halogen, trifluoromethyl, alkyl, alkoxy, methanesulfonyl or trifluoromethanesulfonyl; R.sup.9 is hydrogen or methyl; and Z is O or S,or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to novel compounds which have demonstrated oral antihyperglycemic activity in diabetic ob/ob and db/db mice, animal models on non-insulin dependent diabetes mellitus (NIDDM ot Type II diabetes). These compounds have the formula: ##STR1## wherein: R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, thienyl, furyl, pyridyl, ##STR2## where R.sup.10 is hydrogen, C.sub.1 -C.sub.6 alkyl, fluorine, chlorine, bromine, iodine, C.sub.1 -C.sub.6 alkyoxy, trifluoroalkyl or trifluoroalkoxy;R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl;X is O or S;n is 0, 1, or 2;A is ##STR3## where R.sup.3 is hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, C.sub.1 -C.sub.6 alkoxy, trifluoroalkyl or trifluoroalkoxy;B is ##STR4## where R.sup.4 is hydrogen, C.sub.1 -C.sub.6 alkyl, allyl, C.sub.6 -C.sub.10 aryl, C.sub.6 -C.sub.10 aryl-(CH.sub.2).sub.1-6 --, fluorine, chlorine, bromine, iodine, trimethylsilyl or C.sub.3 -C.sub.8 cycloalkyl;R.sup.5 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.6 -C.sub.10 aryl, or C.

Abstract: This invention relates to novel compounds which have demonstrated oral antihyperglycemic activity in diabetic ob/ob and db/db mice, animal models on non-insulin dependent diabetes mellitus (NIDDM ot Type II diabetes). These compounds have the formula: ##STR1## wherein: X os O or S;n is 0, 1, or 2; ##STR2## A is ##STR3## B is Y is O or S;Z is N or CH when Y is O and Z is CH when Y is S;or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to novel compounds having antihyperglycemic properties of the formula: ##STR1## where A is ##STR2## wherein:n is 1 or 2;R.sup.1 and R.sup.3 are independently hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.1 -C.sub.8 alkoxy, trifluoromethoxy, halogen or trifluoromethyl;R.sup.2 is hydrogen or methyl; andX is oxygen or sulfur or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to compounds which have oral antihyperglycemic activity of the formula: ##STR1## wherein: R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, thienyl, furyl, pyridyl, ##STR2## R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; X os O or S;n is 0, 1, or 2;A is ##STR3## Y is O or S;Z is N or CH when Y is O and Z is CH when Y is S;or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to compounds which inhibit lipoxygenase in the metabolism of arachidonic acid and thus inhibits formation of leukotrienes which are implicated in inflammatory processes and bronchoconstriction and inhibits the oxidation of LDL which is implicated in formation of atherosclerotic plaque.The compounds useful in this invention are represented by the formula: ##STR1## wherein: R.sup.2 is hydrogen, halogen or C.sub.1 -C.sub.6 alkyl; Y of O or S; R.sup.5 is hydrogen or methyl R.sup.6 is --NH.sub.2, --CH.sub.3 or --OCH.sub.3 ;and R.sup.1 is ##STR2## wherein R.sup.7, R.sup.8 and R.sup.10 are independently halogen, trifluoromethyl, alkyl, alkoxy, methanesulfonyl or trifiuoromethanesulfonyl; R.sup.9 is hydrogen or methyl; and Z is O or S,or a pharmaceutically acceptable salt thereof.Compounds of the above formula where R.sup.1 is not ##STR3## when R.sup.3 is H and R.sup.6 is --NH.sub.2 are novel.

Abstract: This invention relates to novel 2-[4-(5-substituted-1,2,4-oxadiazol-3-ylmethoxy)benzyl]-1,2,5-oxadiazolidi ne-3,5-diones which have demonstrated antihyperglycemic activity in diabetic (ob/ob and db/db) mice, genetic animal models of non-insulin dependent diabetes mellitus (NIDDM or Type II diabetes). These compounds are represented by Formula I below: ##STR1## wherein R.sup.1 is C.sub.6 -C.sub.10 aryl, optionally substituted by one to three substituents independently selected from C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, fluorine, chlorine, bromine, iodine, C.sub.1 -C.sub.3 trifluoroalkyl or C.sub.1 -C.sub.3 trifluoroalkoxy; andR.sup.2 is selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 alkyl, fluorine, chlorine, bromine, iodine, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.3 trifluoroalkyl, and C.sub.1 -C.sub.3 trifluoroalkoxy,or a pharmaceutically acceptable salt thereof.